“3 Years of Tralokinumab Treatment Provides Long Term Disease Control As Demonstrated by Clinically Meaningful Outcomes in Modera Te to Severe Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine 7, no. 2 (March 13, 2023): s142. Accessed April 4, 2025. https://skin.dermsquared.com/skin/article/view/2028.